Home
Resources
Publications
[Treatment of Bone Disease in Chronic Kidney Disease and in Renal Transplant Recipients Under K/DOQI Clinical Practice Guidelines]

[Treatment of Bone Disease in Chronic Kidney Disease and in Renal Transplant Recipients Under K/DOQI Clinical Practice Guidelines]

Tadahiko Tokumoto, Kazunari Tanabe, Hiroshi Toma, Takashi Akiba

Clin Calcium. 2004 May;14(5):710-8.

PMID: 15577031

Abstract:

The National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (K/DOQI) provides evidence based clinical practice guidelines developed for all phases of kidney disease and related complications, from diagnosis to monitoring and management. Bone disease sets in during the early stages of Chronic Kidney Disease (CKD). Bone disease is observed in almost patients with chronic renal failure and after renal transplantation. Hyperparathyroid (high turnover) bone disease in patients with chronic renal failure is found most frequently followed by mixed osteodystrophy, low-turn over bone disease, and osteomalasia. Ninety to one hundred percent of kidney transplant patients have histological evidence of osteodystrophy and osteopenia (reduction of bone mass) following renal transplantation. Furthermore, osteoporosis is also appeared in many renal transplant recipients. After renal transplantation, renal osteodystrophy generally improves but bone mineral density (BMD) often worsens. When renal bone disease is assessed using a combination of biochemical markers, histology and bone densitometry, early intervention and carefully effective therapies might be reduced the morbidity associated with these common problems.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
CS31043313	Testosterone Cypionate Related Compound A			Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: